CompletedNCT00568685
Three doses of atomoxetine for children and teens with ADHD in Korea
About this title
Read the official source — NCT00568685Medication studyAges 6–18South Korea
Understand this study
Who was this study for?
Listed age limits: 6 years to 18 years.
- Listed locations
- Bucheon-si and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 153
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- South Korea
- Age range
- From 6 Years to 18 Years
- Official registry ID
- NCT00568685
- Official title
Show the full official title
A Phase 3b, Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine Hydrochloride in Korean Pediatric Outpatients With Attention-Deficit/Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bucheon-si · Incheon · Seoul
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine Hydrochloride and Atomoxetine hydrochloride.
Who was this study for?
Listed age limits: 6 years to 18 years.
